News | Artificial Intelligence | January 03, 2024

K Health to Collaborate with Mayo Clinic on Cardiac Clinical Artificial Intelligence (AI) Solution

Artificial Intelligence (AI)-driven Primary Care company K Health has announced it has entered into a know-how agreement with Mayo Clinic on the development of a cardiac clinical AI solution with the intent to prevent premature deaths from heart disease and stroke.

 

Artificial Intelligence (AI)-driven Primary Care company K Health has announced it has entered into a know-how agreement with Mayo Clinic on the development of a cardiac clinical AI solution with the intent to prevent premature deaths from heart disease and stroke.

Artificial Intelligence (AI)-driven Primary Care company K Health has announced it has entered into a know-how agreement with Mayo Clinic on the development of a cardiac clinical AI solution with the intent to prevent premature deaths from heart disease and stroke. Image courtesy: K Health


January 4, 2024 — Artificial Intelligence (AI)-driven Primary Care company K Health has announced it has entered into a know-how agreement with Mayo Clinic to tackle the prevention and care of heart-related conditions. According to a statement issued by K Health will collaborate with Mayo Clinic cardiologists Francisco Lopez-Jimenez, M.D., M.S., MBA, Chair of the Division of Preventive Cardiology, and Amir Lerman, M.D., Vice Chair of Research at the Department of Cardiovascular Medicine, on the development of a cardiac clinical AI solution with the intent to prevent premature deaths from heart disease and stroke.

The goal of the cardiac program is to use proprietary algorithms built by K Health to power advanced AI-ECG (AI-enhanced electrocardiography) technology, risk assessments, and remote patient monitoring, according to the statement. It further noted this is intended to help physicians personalize treatment for conditions such as hypertension and high cholesterol, or prevent them entirely. Drs. Lopez-Jimenez and Lerman will oversee the development and leverage their real-world insight to evaluate the accuracy and effectiveness.

K Health has licensed de-identified patient data from Mayo Clinic Platform to refine its AI models and develop new algorithms since 2020. The AI models used in this program seek to help physicians predict risk and optimal treatment by accounting for specific factors, such as gender, age, medical history, ethnicity, and more, reported the company.

“Our first step in reducing avoidable cardiovascular deaths was building a machine learning model to allow all hypertension patients to directly benefit from the Mayo Clinic standard of care,” said Ran Shaul, Co-Founder and Chief Product Officer of K Health. Shaul added, “We’re able to help physicians practice more personalized medicine by giving them instant information on their patients, and the know-how of Dr. Lopez-Jimenez and his team are key to bringing our vision of changing the course of heart disease to life.”

According to the World Health Organization, 80% of cardiovascular deaths can be prevented. Proper risk assessment and oversight are key to reducing the number of premature deaths.

K Health provides a 24/7 virtual primary care solution, available to millions of people in the United States through leading health systems and insurers, and through a direct-to-consumer mobile app. The New York-based company reports that its platform includes a medical chat and AI predictive models based on large datasets to help physicians optimize diagnosis and treatment, and focus on patient care.

The project is slated to begin in early 2024, reported the Jan. 3 announcement, which further added: Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

More information: www.khealth.com


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now